Clinical trials located in


Basingstoke city is located in United Kingdom. Currently, 8 clinical trials are being conducted in this city.

Basingstoke, a historic market town in Hampshire, England, has evolved from an old market town into a thriving modern hub. Known for its rich history dating back to the Domesday Book, it now boasts the expansive Festival Place shopping center, attracting shoppers from across the region. The town is also home to the Milestones Museum, showcasing Victorian and 1930s streetscapes. Basingstoke’s Willis Museum traces local history, including a connection to Jane Austen, who lived nearby. The town is surrounded by picturesque countryside, including the North Wessex Downs.

  • CT-EU-00057780

    Study on risk reduction of heart complications with Milvexian

    This study involves a drug called milvexian, which is being tested for people who have recently experienced a heart-related episode, like a heart attack or stroke (acute coronary syndrome). Half of the participants will receive milvexian, and the other half will get a placebo. The study’s main aim is to show that milvexian can help reduce the chance of major heart-related problems happening again. These problems include things like heart failure, another heart attack, or an ischemic stroke.

    • Milvexian
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    • Zanubrutinib
    • Obinutuzumab
    • Lenalidomide
    • Rituximab
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    • Dazostinag
    • Platinum
    • Pembrolizumab
    • 5-Fluorouracil
  • Examining Octaplex’s effect on stopping acute bleeding in patients on blood-thinning drugs

    This is a detailed study that aims to test the efficiency and safety of a medication called OCTAPLEX. The medication is used for patients who are having severe bleeding, and are already on a type of medication known as Factor Xa Inhibitor. Patients will be split into two groups and will receive the medication in either a high or low dosage. The study will observe the participants for 30 days to see how well their bodies are proceeding with preventing the bleeding. They will also be studying various health factors such as body temperature, pulse, breathing rate, and blood pressure.

    • Octaplex
  • Evaluating itch relief in liver disease with linerixibat

    The GLISTEN study is a detailed research project exploring the effectiveness of a medication called linerixibat in treating severe itching in people with a liver condition known as Primary Biliary Cholangitis (PBC). In this study, participants are given either linerixibat or a placebo to see which one better reduces itching and improves sleep and overall quality of life. This research is important for finding new ways to help people with PBC who experience discomfort from itching.

    • Linerixibat
  • Safety and tolerance test of linerixibat for cholestatic pruritus

    The aim of this study is to find out how safe and effective long-term treatment with a drug called linerixibat is in people with primary biliary cholangitis (PBC). PBC is a disease in which bile, which helps digest food, cannot flow properly, causing the skin to become itchy. This study will include people who have already taken linerixibat in previous studies. The study continues until the end or until the drug can legally be administered to patients, depending on how long the patient stays at the facility. Scientists will check for side effects and monitor the patient’s quality of life using questionnaires. These surveys will cover any symptoms, itching, fatigue, mental clarity, social and emotional life. Another questionnaire assesses whether the patient’s health affects his or her daily activities and feelings.

    • Linerixibat
  • Study of new drugs in acute lymphoblastic leukemia

    This clinical trial focuses on improving treatment strategies for acute lymphoblastic leukemia (ALL) in a diverse age group, from infants to young adults up to 45 years old. The study combines standard treatments with new drugs, for example, Inotuzumab Ozogamicin and Blinatumomab. The trial aims to tailor treatment to individual patient needs and reduce toxicity while maintaining treatment quality. By carefully monitoring event- and disease-free survival rates, as well as minimal residual disease responses, the trial aims to improve the standard of care for ALL and improve both survival outcomes and patient quality of life.

    • Inotuzumab Ozogamicin
    • 6-tioguanine
    • Blinatumomab
    • Imatinib
    • Dexamethasone
    • Vincristine
    • Doxorubicin
  • Exploring sacituzumab govitecan for HER2-negative breast cancer care

    This study is evaluating a new treatment for patients with a certain type of breast cancer (HER2-negative) who have not had a complete response to initial chemotherapy. Participants are randomly assigned to receive the investigational drug sacituzumab govitecan or a treatment of their physician’s choice, which may be another type of chemotherapy with capecitabinalub, carboplatin or cisplatin. The study is designed to compare the effectiveness of these approaches in preventing cancer recurrence. Patients may also receive hormone therapy if needed. Patients’ safety and response to treatment are being closely monitored throughout the study.

    • Sacituzumab govitecan
    • Carboplatin
    • Cisplatin
    • Capecitabine

See more clinical trials in other cities in United Kingdom: